Standard usage and dosage instructions of Roprostim (Huierning)

Romiplostim () is a recombinant fusion protein thrombopoietin receptor agonist (TPO-RA), mainly used to treat adult patients with idiopathic thrombocytopenic purpura (ITP). Its mechanism of action is to stimulate the proliferation and differentiation of bone marrow megakaryocytes by simulating endogenous TPO, thereby increasing platelet production. Roprostim is administered as a subcutaneous injection and has a rapid onset of action, improving platelet counts and reducing the risk of bleeding.

AdultsITPThe standard starting dose for patients is 1 μg/kg, administered subcutaneously once a week. After the first dose, platelet levels should be monitored at the same time each week to assess efficacy and adjust dosage. The dosage for pediatric patients needs to be individually adjusted based on body weight, and a once-weekly subcutaneous injection regimen is usually adopted.

Dose adjustment needs to be based on platelet count, and the principle is "gradual increase or decrease". If the platelet level does not reach the target (usually ≥50×10^9/L), the dose can be increased weekly, generally by 1 μg/kg, and the maximum dose does not exceed 10 μg/kg/weeks. If the platelet count rises too fast or exceeds the safe upper limit, the dose should be reduced or the drug should be temporarily discontinued to prevent thrombosis. Through flexible adjustment, platelets can be stably maintained within a safe range.

During treatment with loplastin, platelet counts should be monitored weekly and the dose adjusted based on platelet changes. At the same time, liver function and bone marrow conditions should be evaluated regularly, and patients with long-term use should pay attention to the potential risk of myelofibrosis. Overall, the standard usage and dose design of Roprostim emphasizes individualization, sequential adjustment and safety monitoring to achieve a stable increase in platelets and reduce bleeding events, providing an effective long-term treatment plan for ITP patients.

Reference materials:https://www.drugs.com/